From the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital; Peking University Third Hospital; and General Hospital of Guangzhou Military Command of PLA.
Plast Reconstr Surg. 2022 Dec 1;150(6):1225-1235. doi: 10.1097/PRS.0000000000009732. Epub 2022 Sep 15.
Hyaluronic acid fillers are widely used in nonsurgical rhinoplasty.
The authors performed a no-treatment control, multicenter, 12-month follow-up study to evaluate efficacy and safety of Restylane Lyft (Galderma, Uppsala, Sweden) in shaping the nasal dorsum and radix. Assignment to Restylane Lyft or no-treatment control was randomized (3:1). The Restylane Lyft group received a maximum of 1 ml of Restylane Lyft on day 1; the control group was offered a maximum of 1 ml of Restylane Lyft at month 6. Both groups were offered re-treatment (a maximum of 0.5 ml of Restylane Lyft) at month 12. Outcome assessments included blinded evaluation of three-dimensional photography measurements of change in volume (primary endpoint; month 6) and elevation of the nasal dorsum and radix, aesthetic improvement, adverse events, and diary-reported injection-site reactions.
One hundred thirty-two Chinese subjects were enrolled. The Restylane Lyft group had a greater increase in volume of the nasal dorsum and radix than the no-treatment control (mean difference at month 6, 0.71 ml; 95 percent confidence interval, 0.59 to 0.83 ml; p < 0.001). Restylane Lyft was also more effective than no-treatment control in achieving an elevation of the nasal dorsum and radix. The increase in volume and elevation persisted up to 12 months after injection and was supported by clinical assessments of aesthetic improvement. Treatment-related adverse events were mild to moderate, nonserious, and resolved during the study. Injection-site reactions were mostly mild to moderate and resolved within 1 week.
Restylane Lyft injection was effective for aesthetic shaping of the nasal dorsum and radix and achieved aesthetic improvement for up to 12 months with an acceptable safety profile.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, I.
透明质酸填充剂广泛应用于非手术隆鼻术。
作者进行了一项无治疗对照、多中心、12 个月随访研究,以评估瑞蓝·丽瑅(高德美,瑞典乌普萨拉)在塑造鼻背和鼻根的效果和安全性。随机分配(3:1)接受瑞蓝·丽瑅或无治疗对照。瑞蓝·丽瑅组在第 1 天最多接受 1 毫升瑞蓝·丽瑅;对照组在第 6 个月最多接受 1 毫升瑞蓝·丽瑅。两组在第 12 个月都接受了再治疗(最多 0.5 毫升瑞蓝·丽瑅)。结局评估包括对三维摄影测量体积变化(主要终点;第 6 个月)、鼻背和鼻根抬高、美学改善、不良事件以及日记报告的注射部位反应进行盲法评估。
共纳入 132 例中国受试者。与无治疗对照组相比,瑞蓝·丽瑅组的鼻背和鼻根体积增加更大(第 6 个月时的平均差异为 0.71 毫升;95%置信区间,0.59 至 0.83 毫升;p<0.001)。与无治疗对照组相比,瑞蓝·丽瑅在实现鼻背和鼻根抬高方面也更有效。注射后 12 个月内,体积增加和抬高持续存在,并得到美学改善的临床评估支持。治疗相关的不良事件为轻度至中度,非严重,且在研究期间得到解决。注射部位反应大多为轻度至中度,在 1 周内得到解决。
瑞蓝·丽瑅注射对鼻背和鼻根的美学塑造有效,可实现长达 12 个月的美学改善,且安全性可接受。
临床问题/证据水平:治疗性,I 级。